The companies that struggle most after a Form FDA 483 is issued are often not the ones that lack words. They are the ones who lack control.

That is what the FDA’s March 2026 draft guidance makes clearer than before.

🎥 Prefer a practical walkthrough? Watch the full webinar

The document does not create a new legal standard, and it is still a draft and nonbinding. But it does put in writing, in a much more structured way, what the FDA expects to see when a company submits a response to the FDA 483 form after a drug cGMP inspection.

That was also the central point in our recent webinar. A company’s response to the FDA 483 form is not a writing exercise. It is not a negotiation over wording. It is not a test of how quickly a company can send a polished letter back to the Agency.

It is a test of whether the company actually understands the problem. Not only the words on the form, but the operational, quality, and patient risk behind them.

A weak response answers the observation.

One of the clearest traps companies fall into is treating the FDA 483 like a list of comments to address one by one.

That approach feels efficient. It is usually not enough.

A strong response does more than answer the cited point. It shows that the company has stepped back and asked the harder question: if the FDA found this here, where else might the same weakness exist? That is the real discipline FDA is looking for. Similar products. Similar processes. Related systems. Other equipment. Potential impact on the distributed product. Whether the issue is isolated or whether it points to something broader.

The draft guidance reflects exactly that mindset. FDA recommends a patient- and product-focused risk assessment, including an assessment of inventory and distributed drugs still within expiry, and expects companies to address the scope and whether the issue may be isolated or systemic.

Find out how ADRES can help you align your FDA 483 response with FDA expectations.

Contact Us

So here is the practical distinction. A narrow response reacts to the example the FDA wrote down. A strong response demonstrates that the company understands the system behind the example.

The investigation is where the response usually succeeds or fails

In practice, many company responses to the FDA 483 form are weakened long before drafting starts. They are weakened in the investigation.

That point came through clearly in the webinar. The same familiar issues often sit behind observations: shallow deviation handling, weak root cause work, incomplete follow-through, validation gaps, data integrity concerns, and a failure to ask whether one event is part of a wider pattern.

The common mistake is to stop at the first explanation that sounds plausible. The correct approach is to keep going until the company can show why the issue happened, how far it reaches, and why the proposed corrective action matches the actual cause rather than the most visible symptom.

FDA’s draft guidance is direct on this. It recommends a detailed investigation report covering scope, associated drugs and lots, identified root causes, related systemic issues, CAPA, completed and interim actions, and effectiveness evaluation. It also recommends a scientifically justified, risk-based investigation scope, including justification for exclusions.

That matters because weak investigations do not stay small. A narrow event can quickly become evidence that the quality system is not seeing itself clearly.

The FDA also expects companies to know when outside expertise is needed

Another point that should not be overlooked is the FDA’s express recognition that external expert support may be appropriate.

The draft guidance states that a consultant may be useful for additional insight to understand and assess inspectional observations and to develop an appropriate CAPA plan. FDA goes further in cases involving data integrity findings, where it recommends engaging a cGMP consultant.

This is an important practical point. In complex cases, an experienced external consultant can help the company test whether its response logic is strong enough, whether the investigation scope is too narrow, whether the root cause analysis is adequately supported, and whether the overall company response to the FDA 483 form is written in the manner, structure, and scope FDA expects.

This is not about outsourcing responsibility. The company remains fully responsible for the content, commitments, and execution. But using an expert consultant can help validate that the response is not only technically sound but also organized in a way that makes the FDA’s review easier and more credible.

That can be especially valuable when the company is under time pressure, dealing with repeat observations, responding to broad system deficiencies, or preparing a response that may affect a pre-approval timeline.

Executive management is not a sign-off layer. It owns the response.

Another important point, both in the guidance and in the webinar, is that a company’s response to the FDA 483 form is not just a QA document.

It is a management commitment.

FDA says the response should identify who prepared it and should be signed by executive management with the authority to allocate resources and implement commitments. The guidance also places responsibility on management to assess risk, support the investigation, and ensure adequate resources for remediation.

That is not a formality. It has operational meaning.

When executive management signs a company’s response to the FDA 483 form, the company is not only saying it understands the observation. It says it is prepared to commit people, time, budget, and organizational attention to fixing the issue properly. That means the response cannot remain trapped inside QA. It requires cross-functional ownership across quality, manufacturing, technical operations, regulatory, and leadership.

Strong companies understand this early. Weaker companies discover it late.

The executive summary matters because it exposes whether the remediation plan is real

FDA’s draft guidance includes an executive summary table. It would be easy to dismiss that as a presentation.

It is not.

A structured summary forces discipline. It requires the company to show, in one place, what the observation is, which system it belongs to, what CAPA it ties to, what has already been completed, what interim controls are in place, what target dates exist, and what remains open.

FDA’s example includes fields such as the observation number, general category or system, summary, CAPA number, target date including interim actions, and current remediation status.

That is useful not only for FDA review. It is useful internally because it reveals very quickly whether the company has a real remediation program or only a loose collection of intended actions.

The 15-business-day window is more serious than many teams still assume

The draft guidance sharpens the practical meaning of timing.

The FDA recommends one complete company response to the FDA 483 form addressing all observations within 15 business days. For complex issues that cannot be fully resolved in that period, the FDA recommends that companies still submit a CAPA plan, interim measures, and a proposed timeframe for substantive follow-up within that same window. The guidance also states that the FDA will not ordinarily delay regulatory action, such as a warning letter, to review a response received after that period.

That changes the way companies should think about the first response.

The first response does not need to claim that everything is finished. It does need to show seriousness. It should show that the company has assessed risk, started the right investigation, defined interim protections, assigned ownership, and built a credible path to completion.

This is especially important in pre-approval settings, where the effect of a weak or delayed response can have a direct impact on product approval.

Repeat observations are not about memory. They are about system credibility.

One of the most practical lessons from the webinar was the focus on repeat observations.

FDA does not look only at each observation in isolation. It looks for patterns. If similar issues recur across inspections, or if related gaps appear across multiple systems during the same inspection, the message becomes much more serious.

The draft guidance tells companies to review past inspections and internal audits for repeat observations or similar trends, and notes that this trend review may highlight a systemic issue at a facility or across an organization.

That is why companies should read a 483 in two directions. First, observation by observation. Second, as a whole. The second reading often tells you more about regulatory risk than the first.

CAPA should start during the inspection, not after it

Another practical point from the webinar was timing inside the inspection itself.

Companies should not wait until the company’s response to the FDA 483 form is being drafted to start building their CAPA logic. They should begin assessing risk, clarifying issues, and identifying real corrective actions while the inspection is still underway.

FDA’s draft guidance aligns with that approach. It says establishments are encouraged to begin developing a CAPA plan during, or immediately after, the inspection.

That does not mean cosmetic fixes. It does not mean rewriting a procedure and hoping that counts as remediation. It means starting the real work early enough that the eventual response reflects actual operational thinking rather than post-inspection improvisation.

Disagreements should be raised early, calmly, and with evidence

Not every observation has to be accepted without question.

Scientific and technical disagreements do arise. But the difference between a credible disagreement and a weak one is method.

FDA says companies should seek clarification with FDA representatives during the inspection when scientific or technical disagreements arise, and unresolved disagreements can then be addressed in the company’s response to the FDA 483 form.

That is also the practical discipline companies should adopt. If the company believes the investigator misunderstood a process or reached the wrong technical conclusion, the response should be grounded in data, applicable regulations, guidance, standards, and clear scientific reasoning.

Not defensiveness. Not tone. Evidence.

What companies should revisit now?

The practical takeaway is not complicated.

Companies should revisit how they scope a company response to the FDA 483 form. They should test whether their investigations truly reach the root cause. They should make sure CAPA plans are tied to risk, ownership, interim controls, timelines, and effectiveness checks. They should also consider when an experienced external consultant can strengthen the assessment, validate the response approach, and help ensure the package is structured in the way the FDA expects. And they should ensure leadership understands that the response is an organizational commitment, not a document that QA prepares in isolation.

That is why the March 2026 draft guidance matters. Not because it changes everything. Because it makes the standard for a credible response much harder to pretend not to understand.

Watch the full webinar

For the full discussion, including practical examples on scope, repeat observations, management responsibility, CAPA timing, use of expert consultants, and how to handle technical disagreements, watch the webinar recording here

This webinar, triggered the revision of PDA TR56 that was revised in 2026, demonstrate the shift of questions, from “At what point do we need GMP?” to “What must be robust now, and what can by mature later?” Watch Tamar Oved, PhD explaining the practical, phase-appropriate execution.

PDA Technical Report No. 56 is a long-used reference for phase-appropriate quality systems and GMP for biological drug substance. The 2026 revision of this guideline triggered this overarching webinar, relating to GMP implementation at different development phases. For sponsors and CDMOs, the practical goal is to build a fit-for-purpose quality system that supports safe clinical supply and scales as programs accelerate, without overbuilding early systems.

The core message

Phase-appropriate does not mean minimal. It means structured and risk-based.

As product and process knowledge increases, rigor and documentation should step up in a deliberate way. This matters even more when timelines compress. Expedited pathways and parallel activities often require stronger controls earlier than teams planned.

What teams should revisit now

In the webinar, Tamar highlights where teams commonly underbuild early and then pay for it later through comparability questions, and quality system catch-up.

1. Quality risk management that drives decisions

Risk assessments work best as a lifecycle tool. Use them to set control strategy now, and to define clear triggers for step-ups in rigor later.

2. Sponsor oversight when work is outsourced

Outsourcing does not outsource accountability. Even when manufacturing and testing sit with a CDMO, the sponsor remains responsible for key quality decisions, oversight, and release readiness.

3. Documentation and data integrity

Early development data becomes foundational faster than teams expect. Weak documentation and data integrity early often creates painful reconstruction later when decisions, changes, and continuity must be justified.

4. Method lifecycle, specifications, and comparability planning

Methods and specifications evolve across phases. The practical goal is to plan that evolution so method changes, tightened criteria, and shifts in testing strategy do not create avoidable comparability issues.

Practical next steps checklist

Use these questions to translate the phase-appropriate approach into execution:

• Are the basics in place before Phase 1 (controlled records, documentation practices, calibration and maintenance)
• Do we have a risk approach that is proportionate now and scalable later?
• Is sponsor oversight of outsourced work clearly defined (quality agreement, escalation paths, release responsibilities)?
• Can we trace key development decisions and changes without reconstructing history?
• Do we have a plan for method qualification and validation by phase, including how method changes will be managed?
• Do we have a comparability plan as the process evolves, with clear triggers for deeper studies?
• Are quality system upgrades aligned to the program’s realistic pathway, including potential acceleration?

Watch the 45-minute session to get the practical takeaways and a clear execution approach.

Speaker

Tamar Oved, PhD – QA and CMC Director, ADRES Advanced Regulatory Services

About ADRES

ADRES provides international biotech consultation and execution, with integrated regulatory, QA, and CMC support to help teams build phase-appropriate systems that meet current expectations from early development through later phases.

Biomed startups need earlier human data to make clear go or no-go decisions before the runway runs out. Israel offers a practical way to reach first-patient results faster, with strong oversight and costs a startup can carry.

Israel works because three pieces line up. The Ministry of Health applies a risk-based review that allows sensible deferrals when patient safety is unchanged. The national HMOs provide digitized longitudinal records that support cohort pre-verification before you open recruitment. The sites are experienced with focused, early studies that prioritize clean execution over scale. Put together, you move from award to first visit in weeks rather than quarters, and you do not trade quality for speed.

Founders struggle most with timelines that drift.

In Israel, the path is clearer because key steps run in parallel. While your team finalizes the protocol and localizes documents, the MoH review can begin with a tight risk file and plain-English rationale for each change. In the same window, sites prepare logistics and query HMO data against your inclusion rules to identify likely matches. By the time approval lands, you are not starting from zero. You are ready to consent and screen with confidence that the pool exists.

Recruitment is the decisive edge.

Pre-verification against real records reduces screen failure, shortens the ramp, and narrows variance around your enrollment forecast. You know whether the cohort is there, where they receive care, and how to structure outreach that respects privacy and consent. This is not a shortcut. It is disciplined feasibility that removes guesswork before you spend on monitors, pharmacy, imaging, and idle site weeks.

Costs follow the same logic.

When cycle slips disappear, paid idle time drops. When you concentrate work in a few capable centers with proven access to the target population, you avoid the long tail of under-performing sites that enroll one patient each. Local rates for monitoring and select vendors are often lower than U.S. equivalents, which compounds the savings for Phase 1, 1b, and device feasibility programs. The important part is to capture these gains in contracts up front and to hold vendors to milestones that reflect the parallel work model.

Many teams now design patient-cohort add-ons that sit between a classic healthy-volunteer start and a larger Phase 2. The aim is an earlier signal in the target disease with biomarkers that de-risk dose, schedule, or device parameters. Keep these cohorts tight. Limit endpoints to those that change decisions. Blend EHR pulls for routine measures with focused study visits for what cannot be captured in care. You get sharper data without bloating the protocol.

A hybrid model often delivers the best of both worlds. Run a lean Israeli engine to reach first-patient data and pair it with one or two U.S. sites for KOL engagement and downstream regulatory alignment

Quality and oversight remain non-negotiable.

A monitoring plan should reflect actual risk and the specifics of your modality. Centralized review for safety labs, imaging, or device telemetry reduces variability and speeds detection of issues. Many operators run a brief enrollment pause after the first few patients to validate the consent flow, assess sample handling, and confirm endpoint capture. Small fixes at this stage prevent expensive rework later.

Data governance needs the same attention as science.

Work through HMO governance channels early. Start with de-identified feasibility queries to confirm that your criteria map to a real population. Align consent language so patients understand how routine care data link to study data, and so transfers remain minimal and auditable. If you keep data moves narrow and transparent, you protect patients and stay inspection-ready.

Israel is not a universal fit. If your indication is ultra-rare with minimal local prevalence, recruitment will not meet expectations. If your device requires complex hardware that is not available locally, setup time can erase the advantage. If your internal team cannot meet weekly decision cadence, the benefit of parallelism fades. In these cases, adapt the plan or select a different path rather than forcing a model that does not match your constraints.

A hybrid model often delivers the best of both worlds. Run a lean Israeli engine to reach first-patient data and pair it with one or two U.S. sites for KOL engagement and downstream regulatory alignment. Keep the protocol identical and the data systems unified to avoid splitting the study by accident. This structure supports both speed and credibility with partners who expect U.S. touchpoints.

If you need a framing for your next decision meeting, use five questions:

• What single decision must this study inform, and by what date?
• Does HMO feasibility show enough candidates under your criteria?
• Which elements of the submission can be safely deferred without changing patient risk?
• Where exactly will savings come from, and how will contracts lock them in?
• Which partners already have live HMO connections and MoH experience for your modality?

Clear answers to these questions prevent drift and protect milestones tied to your financing.

The recent webinar explored this operating model with voices from sites, HMOs, and startup clinical leaders who have delivered on these timelines. It was not a recap of guidelines. It was a working playbook with concrete examples of approvals, startup flow, and cohort management. If you want color on the mechanics or vendor choices, the session is a good companion to this article.

In short, Israel gives biomed startups a credible route to earlier human data with tighter timelines, faster recruitment, and thoughtful cost control. Plan parallel work, verify cohorts before you open, and keep quality measures precise. If you want to test whether this model fits your program, watch the webinar and then reach out with your specific constraints.

For questions or a quick fit check – contact us

Preparing for a U.S. FDA inspection, EMA audit, or any other regulatory review isn’t just another box to check. It’s a strategic lever for accelerating approval timelines, reducing risk, and safeguarding your product’s credibility. In the life sciences, where delays can cost millions and stall lifesaving treatments, being truly inspection ready is a business imperative.

Why Inspection Readiness Matters

For companies submitting BLA, NDA, or MAA applications, inspection outcomes often determine whether those filings will proceed smoothly or hit costly roadblocks. Regulatory authorities don’t just evaluate your data. They examine the integrity of your systems, the preparedness of your staff, and the reliability of your vendors. That’s why inspection readiness must be treated as an ongoing organizational capability, not a last-minute fire drill.

From Reactive to Proactive: What It Means to Be Inspection Ready

Being inspection ready means your systems, documentation, and people can withstand regulatory scrutiny at any time. It’s not just about compliance. It’s about creating a culture of quality aligned with global standards like ICH Q10, ICH E6(R2), 21 CFR Part 11, and EU GMP Annex 1 and 11.

This involves more than keeping documents in order. It means ensuring that clinical and manufacturing data are traceable, vendors meet your standards, and your team knows how to engage with regulators when the moment comes.

Key Steps to Building an Inspection Readiness Plan

A structured readiness strategy focuses on six core areas:

1. Closing the Gaps Before Inspectors Find Them

Start with a comprehensive gap analysis. Review processes across clinical operations, GMP manufacturing, data systems, and your Quality Management System (QMS). Use a risk-based approach in line with ICH Q9 to prioritize and remediate weaknesses.

This early assessment not only prevents regulatory surprises but also provides clarity on where to invest your resources for the biggest compliance impact.

2. Simulating the Real Thing with Mock Inspections

Nothing prepares teams better than a live drill. Mock inspections, ideally led by former FDA or EMA inspectors, simulate real-world audits. These exercises test everything from document access and SOP walkthroughs to how well your staff communicates with regulators.

A regulatory audit simulation reveals practical issues, such as poor documentation retrieval or inconsistent answers, that can derail an actual inspection.

3. Ensuring Data Integrity Through Source Data Verification

During inspections, regulators will trace reported results back to their original source documents—from batch records and lab notebooks to CRFs and electronic audit trails. That’s where Source Data Verification (SDV) comes in.

Using frameworks like ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available), SDV confirms that your data is credible, consistent, and submission-ready.

Lack of traceability is a frequent trigger for Form FDA 483 observations or even Complete Response Letters (CRLs). With SDV, you strengthen your inspection resilience and your case for approval.

4. Training Teams for Real Inspection Scenarios

You can’t fake readiness. Inspectors quickly sense whether your team understands GCP, GMP, and your internal SOPs. That’s why ongoing training is essential.

Go beyond basics. Ensure your staff knows how to manage deviations, document properly, and interact professionally with inspectors. Keep training logs current and retrain as systems or regulations evolve.

5. Oversight Beyond Your Walls: Managing Suppliers and CMOs

In the eyes of regulators, you are fully responsible for your third parties. That includes CMOs, CDMOs, CROs, and testing labs.

Your inspection readiness hinges on their compliance too. You’ll need robust Quality Agreements, vendor audits, and documented supplier qualifications that align with ICH Q10. Regulators will ask to see your vendor ratings, CAPA records, and oversight plans.

Any failure at the vendor level can jeopardize your submission. Don’t assume compliance. Demonstrate it.

6. Applying Risk-Based Vendor Qualification

Use tools like FMEA and heat maps to assess and prioritize vendor risks. This helps decide who to audit and when. It also documents rational oversight strategy regulators expect to see.

How Inspection Readiness Supports Submission Success

Most inspections are scheduled during the review window for submissions. If your site or supplier fails during this time, the consequences are immediate—delays, rejections, and lost opportunities for expedited pathways like FDA’s RTOR or EMA’s PRIME.

Investing in inspection readiness early ensures your application isn’t stalled by preventable issues.

What Documentation Must Be Inspection-Ready?

Inspectors typically request:

• Clinical Trial Records: Protocols, consent forms, CRFs, AE reports
• Manufacturing Documentation: Batch records, PPQ reports, trend analyses, stability logs
• Quality System Files: CAPAs, deviations, internal audits, SOP changes
• Third-Party Oversight Materials: Audit reports, Quality Agreements, vendor certifications
• Make sure all documents are easily accessible, traceable, and aligned with eCTD structures, particularly Modules 1.3 and 3.2.
• The Role of Expert Consultants
• Both FDA and EMA strongly recommend engaging GMP/GCP consultants, especially for novel therapies or emerging biotechs. They offer:
• Deep regulatory knowledge
• Independent assessments
• Customized training
• Direct support during inspections and audits
  

Working with a consultant ensures you aren’t navigating inspection risks alone. It signals to regulators that you’re serious about quality.

Why ADRES?

At ADRES, we provide integrated support across regulatory affairs, QA, and CMC to help life science companies meet inspection standards and accelerate approvals. Our offerings include:

End-to-end gap assessments

Mock inspections with ex-regulators

Source data verification and audit readiness

Training programs on GCP/GMP practices

Full-spectrum vendor qualification and monitoring

Partnering with ADRES reduces inspection-related delays, maintains data integrity, and ensures a smoother path to market.

Medical Quality Assurance (QA) in clinical trials is more than a regulatory requirement. It is the foundation for reliable data, patient safety, and efficient approvals. Whether the focus is a pharmaceutical, biologic, or medical device, integrating QA from the start can determine how effectively and confidently a product moves through development.

Clinical trials are inherently complex. Multiple stakeholders, systems, and regulatory expectations intersect, and this complexity increases the risk of inconsistency, delays, and compliance gaps. QA provides a structured, proactive way to manage these risks. It enforces process discipline and regulatory alignment across the entire trial lifecycle. Rather than being a final checklist, QA is a central pillar from day one.

Why QA Matters in Clinical Trials

At its core, Medical Quality Assurance ensures that clinical trials are conducted in a way that safeguards patients and produces reliable data. While Quality Control (QC) focuses on verifying outputs after they are generated, QA is about building sound processes that prevent problems from occurring in the first place.

This distinction has practical consequences. A well-functioning QA program lowers the likelihood of protocol deviations, data integrity problems, and regulatory challenges. When managed correctly, QA reduces rework, supports faster timelines, and keeps your trial on track for inspection readiness.

One area where QA shows measurable impact is protocol adherence. Regulatory inspections often highlight protocol deviations as a top issue. These deviations can usually be avoided through targeted QA measures, including early site oversight, clear staff training, and active tracking of quality metrics. Fewer deviations lead to better data and faster approvals.

The Regulatory Landscape for QA

QA in clinical trials must align with a wide array of national and international regulations. In the United States, the FDA provides key guidance through:

21 CFR Part 211, which outlines good manufacturing practices for finished pharmaceuticals

21 CFR Part 312, covering Investigational New Drug (IND) requirements

21 CFR Part 820, which governs quality systems for medical devices

21 CFR Parts 600 to 680, which apply specifically to biologics

In the European Union and globally, additional frameworks apply. These include:

Directive 2001/83/EC, which regulates medicinal products

EU MDR (2017/745) and IVDR (2017/746), which focus on medical devices and diagnostics

ICH Guidelines, including E6(R2), Q8, Q9, and Q10, which address good clinical practice, development principles, and pharmaceutical quality systems

ISO 13485 and ISO 14155, which govern medical device quality and clinical investigations

At ADRES, we continuously monitor regulatory changes and help sponsors build QA programs that stay in step with evolving global standards.

Responsibilities of Sponsors

Regulators expect sponsors to take full ownership of trial quality, not only for internal processes but also for outsourced activities. That includes work performed by CROs, laboratories, technology vendors, and other partners. To meet this expectation, sponsors must establish and maintain several core oversight practices:

Vendor qualification and selection based on objective, documented criteria

Defined roles and communication pathways through contracts and quality agreements

Routine performance evaluations, SOP reviews, and vendor audits

Corrective and Preventive Actions (CAPAs) that are tracked and verified for effectiveness

Data oversight guided by ALCOA+ principles and supported by risk-based monitoring

Validation of computerized systems, following 21 CFR Part 11 and EU Annex 11 requirements

QA helps sponsors demonstrate that they are in control, not just of their own processes but of the entire clinical trial ecosystem.

What an Effective QA Program Looks Like

A good QA program does not just satisfy compliance requirements. It supports operational efficiency and scientific integrity. Foundational elements typically include:

SOPs that reflect current regulatory expectations

Targeted training that clarifies roles and responsibilities

Risk-based quality management (RBQM) practices that prioritize oversight

Tracking of Key Quality Indicators (KQIs) and compliance metrics

Internal audits and Trial Master File (TMF) health checks

At ADRES, we focus on helping sponsors build QA frameworks that are flexible, effective, and grounded in everyday operations.

The Value of QA Audits

Quality Assurance audits offer a strategic advantage when designed well. They provide early visibility into risks and opportunities for improvement. Best practices for QA audits include:

A risk-focused audit plan that concentrates on critical areas such as informed consent, SAE reporting, and investigational product handling

Standardized checklists and workflows for consistent documentation

Interviews that verify procedural understanding among site and sponsor staff

CAPA documentation and follow-up assessments to ensure resolution

Our audit process at ADRES is built around practical value. We help clients move beyond box-checking to uncover real insights and implement meaningful improvements.

Supporting Patient Safety and Study Outcomes

At every stage, QA protects the integrity of your study and the safety of the patients involved. Key QA activities include:

Oversight of informed consent and inclusion criteria

Monitoring of Serious Adverse Event (SAE) reporting and follow-up

Verification of source data, dosing, and lab results

Readiness reviews to prepare for audits and inspections

These measures build trust, both internally and with regulators. They also help ensure that trial results are credible and reproducible. At ADRES, we specialize in helping sponsors establish QA programs that are practical, risk-based, and aligned with global requirements. Whether your team is preparing for a submission or managing a complex, multi-country study, a strong QA foundation supports better decisions and stronger outcomes throughout the clinical journey.

Are NB backlogs, Article 61 clinical evidence or legacy-device deadlines keeping you up at night?
Watch this 60-minute replay as Salih Oğuz Savaş, Rivka Zaibel and Roy Zaibel unpack the 14 hottest MDR questions and share practical, insider tips.

Speakers

• Salih Oğuz Savaş – Deputy General Manager & Head of Notified Body NB 2975, Szutest Konformitätsbewertungsstelle GmbH, Frankfurt am Main, Germany (de.linkedin.com, szutest-germany.de)
• Rivka Zaibel – President & Founder, ADRES Advanced Regulatory Services Ltd.; 35 + years in biopharmaceutics, QA & regulatory strategy (il.linkedin.com)
• Roy Zaibel – Co-CEO, ADRES & Editor of The Bio-Startup Standard (il.linkedin.com)

Don’t risk delays. Watch now and get actionable answers!

What is a Notified Body (NB)?

A Notified Body is an independent organisation, authorised by an EU/EEA competent authority, that assess your device and quality system against the Medical Device Regulation (MDR 2017/745).
Except for a basic, self‑certified Class I device (non‑sterile, non‑measuring, non‑reusable), and non-class III custom made devices,  every product needs a positive NB conformity‑assessment decision before you can apply the CE mark plus the NB’s four‑digit ID and place it on the EU, EEA or Northern Irish market.

Can I move my MDR application or certificate to a different NB?

Yes, you can transfer an active MDR application or an issued certificate (Article 58, MDR).
Provide:

1. A termination letter from your current NB
2. A full application dossier for the new NB
3. A transition plan covering every technical‑file element
4. Proof that ongoing surveillance will not be interrupted

Acceptance of well‑organised transfers for most devices take two to three months. If your timeline or dossier looks weak, the incoming NB can refuse the project.

Why are more companies requesting NB transfers?

Capacity remains tight: only about forty‑four NBs are designated under the MDR compared with more than eighty under the old Directives. Some have limited product scopes or long backlogs; others have merged or exited. Regulation (EU) 2023/607 extended several deadlines, so many firms now have time to switch.

How long does it take from “hello” to a CE certificate?

With a complete technical file and a mature ISO 13485 QMS, expect:

• Class IIa: about 12 to 18 months
• Class III / implantable: about 15 to 24 months

Main variables: Technical Documentation quality, the speed of your answers to NB questions, reviewer availability, and audit scheduling.

After a successful QMS audit, when will I see my certificate?

You will receive the certificate only when all conformity‑assessment steps have closed (technical‑file review, audit, and final NB decision). The decision phase alone now averages four to ten weeks.

What does Article 61(10) mean for clinical evaluation?

Article 61(10) lets you rely on bench, technical, biocompatibility, and usability data alone when direct clinical evidence would be meaningless (for example, sterilisation devices, patient‑positioning aids. You must still compile a full Clinical Evaluation Report (CER) that justifies this pathway, and your NB must agree. It is not a shortcut for therapeutic devices that could feasibly generate clinical data.

How do I transition a legacy MDD device to the MDR?

Regulation (EU) 2023/607 imposes two pre‑conditions:

[Deadline alert: 26 September 2024] You must:

1. Run an MDR‑compliant QMS, and
2. Hold a signed NB contract.

If you meet those points:

• Class III and Class IIb implantables may stay on the market until 31 December 2027.
• All other Class IIb, IIa, and I devices may stay until 31 December 2028.

Use that time to close evidence gaps (see MDCG 2020‑6) and keep your post‑market surveillance (PMS) and post‑market clinical follow‑up (PMCF) plans current and linked to the risk file.

Can I submit my technical documentation in stages (“rolling” submission)?

Possibly. During the transition period only, many NBs accept an Incomplete Activities Declaration (MDCG 2022‑11). List every missing test or report with a firm delivery date. Essential documents (CER, risk management, PMS/PMCF plans) cannot be deferred. If you miss a milestone, the NB may pause or terminate the review. After 2028, staged submissions will disappear.

What is a “structured dialogue” with an NB?

A structured dialogue is a formal, written Q&A that clarifies MDR clauses, audit sequencing, or NB scope. It is not consultancy and does not pre‑approve a clinical study;  expert panels may be consulted for study plans.  

Are aesthetic devices such as HIFU skin‑tightening or laser‑lipo now regulated?

Yes. Listed Annex XVI devices must meet MDR safety and performance rules and forthcoming Common Specifications.

• If you claim a medical benefit, follow the full MDR route.
• For purely aesthetic benefits, NB involvement is still mandatory, but you demonstrate performance rather than therapeutic benefit.

What if I spot missing or incorrect data after submission?

Tell your NB immediately, submit a corrective‑action plan, and redo any tests or clinical work if needed. Hiding problems almost always triggers a major non‑conformity and rejection.

How do NBs judge “state‑of‑the‑art” performance?

They benchmark your device against harmonised standards, MDCG guidance, competitor data, and current clinical practice. A dedicated state‑of‑the‑art section plus clear comparison tables in your CER prevents most extra NB questions.

What MDR reforms are coming?

Draft measures include:

• Statutory NB review timelines
• An e‑certificate module in EUDAMED
• An  extended “well‑established technologies” list
• Lighter re‑certification activities
• Clarification on change significant changes
• Clarification on the role of Notified Body for vigilance reporting

All aim to cut red tape while protecting patients.

How can I speed up MDR certification?

1. Self‑audit early with MDCG checklists.
2. Submit bookmarked PDFs – one requirement per file.
3. Answer NB questions within ten business days.
4. Maintain a single, live revision log.
5. Finalise your PMS and post‑market clinical follow‑up plan before applying, and link both to the risk file.

This article draws on insights shared during a recent expert-led webinar featuring Rivka Zaibel, President and Founder of ADRES, and Diana Andrade, Founder & Managing Director of RD Privacy. Their combined expertise in GCP compliance and GDPR regulation provides a solid foundation for the following guidance on how sponsors can effectively navigate their responsibilities when selecting and managing vendors in clinical trials.

The Evolving Expectations in Clinical Trials

Recent updates to the ICH GCP guidelines, particularly Revision 3, have placed sharper focus on sponsor oversight. The revisions make explicit what was once implied: sponsors must proactively ensure that all aspects of a clinical trial—from design to data integrity—meet high standards of quality and regulatory compliance. This includes:

• Performing early risk assessments
• Conducting thorough vendor qualification and requalification
• Auditing clinical sites and operations
• Validating computerized systems

These activities are no longer optional best practices; they are regulatory expectations. Section 3.9.1 of ICH E6(R3) specifies that the sponsor must ensure that the trial design and conduct result in reliable data and the protection of trial participants. This translates to clear documentation, traceability, and robust systems that prevent, detect, and correct deviations.

What to Include in Vendor Contracts

Vendor agreements should function as both legal safeguards and operational playbooks. They must:

• Mandate adherence to trial protocols and regulatory standards
• Define data recording and retention responsibilities
• Allow audits and inspections by regulatory bodies
• Address cross-border data handling, language considerations, and time zone coordination

Sponsors must also establish clear lines of responsibility, especially in multi-vendor environments. Agreements should outline escalation procedures in case of deviations and ensure vendors agree to inspections by authorities such as the FDA or EMA.

Data Privacy is Everyone’s Business

GDPR adds another layer of complexity. Under this regulation, sponsors are data controllers—ultimately accountable for how personal data is processed throughout the trial lifecycle. Compliance requires:

• Rigorous due diligence on vendor security practices
• Data Processing Agreements (DPAs) to govern roles, responsibilities, and breach response protocols
• Transfer Impact Assessments (TIAs) and Standard Contractual Clauses (SCCs) for vendors outside the EEA

Documentation is critical. Sponsors must maintain a Record of Processing Activities (ROPA) and conduct Data Protection Impact Assessments (DPIAs) for each trial that poses a high risk to participant rights. During vendor audits, ensure subprocessors are disclosed and approved, and that policies for data subject rights and breach response are in place.

Guidance for Compliance: Beyond the Basics

The webinar highlighted best practices sponsors should implement:

1. Integrated audits: Conduct GCP and GDPR audits in tandem to streamline oversight and avoid compliance gaps.
2. Early engagement of a DPO: Data Protection Officers should review all processing activities and vendor contracts from the start.
3. Policy-driven oversight: Sponsors should implement SOPs on breach notification, data subject rights, and subcontractor approval.
4. Training: GDPR literacy among trial staff is essential, even for non-legal roles. Staff must recognize compliance risks and know how to respond.

Lessons from the Field

Vendor missteps can have serious consequences. In one illustrative case, a sponsor nearly enlisted a trial site with an unresolved FDA warning letter. The oversight could have been caught earlier through a regulatory check. In another example, unclear data transfer agreements led to delayed startup times across multiple geographies.

To avoid such issues, sponsors should treat vendor selection as a strategic decision, not just an operational one. Build in checkpoints for performance evaluation, require transparent metrics from vendors, and have a defined escalation path for compliance concerns.

Small Sponsors, Big Stakes

For small biopharma firms, the regulatory burden may feel outsized. But scalable solutions exist:

• Appoint a quality assurance lead early in development
• Develop a core set of SOPs tailored to your trial’s complexity
• Leverage experienced consultants for both GCP and GDPR compliance
• Use predefined audit templates and questionnaires to assess vendors systematically
• Invest in training so internal teams can identify and mitigate risks early

Small organizations can be just as compliant as large ones if they are proactive and strategic.

Conclusion

Vendor selection in clinical research isn’t just a procurement task—it’s a cornerstone of trial integrity and regulatory compliance. By approaching vendor partnerships with diligence, transparency, and foresight, sponsors can safeguard not only their studies but also the rights and data of their trial participants.

Compliance, in the end, is not a box-ticking exercise. It’s a mindset. Sponsors who embrace this will be better equipped to navigate the increasingly complex terrain of global clinical research.

Looking for expert guidance?

🔹 Connect with ADRES for strategic GCP and quality assurance support tailored to startups and growing biopharma companies. www.adres.bio

🔹 Need help with GDPR compliance? Reach out to RD Privacy for hands-on support in data protection strategies and vendor oversight across clinical trials. www.rdprivacy.com

In July 2023, the FDA issued a warning letter to Intas Pharmaceuticals Limited, citing critical data integrity lapses. These included aborted chromatographic sequences, inadequate oversight of CGMP documents, and insufficient controls over computerized systems. The FDA found instances where laboratory staff aborted chromatographic runs without investigation, raising concerns about the reliability of analytical data. These oversights pointed to a lack of a robust data integrity culture.

This example underscores that data integrity isn’t merely about compliance checklists. It requires embedding a culture where every team member values accurate and reliable data. For startups, building this culture early is essential for long-term success and operational resilience.

Why Culture Matters

One of our client’s CDMOs failed to maintain proper source data for analytical method validation, leading to delays and costly rework during their regulatory submission. This wasn’t just a technology issue but a reflection of an organizational culture that didn’t prioritize DI. A robust DI culture acts as the glue that binds all compliance and operational activities. Without it, even the most advanced systems and processes can fail.

Startups, in particular, face challenges because they often lack dedicated compliance teams. Instead, DI responsibilities are distributed among employees who are more focused on scientific and operational goals. This dual responsibility makes it even more crucial to embed DI into daily activities.

Practical Steps to Build a DI Culture

1. Leadership Commitment: Change starts at the top. When leadership prioritizes DI and visibly supports initiatives, employees are more likely to follow suit. Regularly communicate its importance and link it to the company’s mission.
2. Comprehensive Training: DI training should go beyond explaining guidelines. Use real-world examples to illustrate the consequences of failures and successes. For example, during an audit for one of our clients at their facility, employees ignored critical system error messages instead of reporting them, potentially compromising data. Training emphasized the importance of addressing such errors to prevent similar risks.
3. Empower Employees: Employees are often the first to identify potential DI issues. Create an environment where they feel empowered to raise concerns without fear of repercussions. Encourage feedback and suggestions on improving DI processes.
4. Align Incentives: Avoid creating incentives that conflict with DI principles. For instance, a company that prioritized speed and success in tests over accuracy found employees bypassing controls to meet performance targets, jeopardizing data reliability.
5. Integrate DI into KPIs: Measure and reward adherence to DI standards. KPIs can include audit compliance rates, training completion, and incident reporting.

The Role of Technology

While culture is the foundation, technology plays a supporting role. For example, one QC lab configured its systems to restrict access and monitor activities using audit trails, reinforcing DI principles. Another team reformatted invalid Excel sheets used in bioanalytical services, securing the source data and ensuring verification processes aligned with DI standards. However, these tools are only effective when paired with a workforce that understands and values their purpose.

Many startups seek mock inspection services to evaluate their compliance readiness before regulatory reviews. Additionally, ensuring chemistry manufacturing controls meet industry standards plays a vital role in maintaining data integrity.

Building a DI culture is an investment in your company’s future. It not only ensures compliance but also strengthens investor confidence and operational efficiency. By embedding DI into your organization’s ethos, you set the stage for sustainable growth and innovation.

You are invited to watch the next YouTube video for more information on the topic

Unlocking the Mystery of 21 CFR Part 11 Compliance

One of the most common challenges for startups is navigating the labyrinth of regulatory requirements—particularly when it comes to computerized systems validation (CSV). Take, for example, a biotech company that invested in a lab system advertised as “21 CFR Part 11-compatible.” They rested assured, believing that the vendor’s certification guaranteed compliance. However, they later discovered that accessing the system’s audit trail required vendor intervention, a process that introduced delays and increased costs. This scenario highlights a critical misconception—compatibility does not equate to compliance, and relying solely on vendor assurances can leave companies vulnerable.

Understanding 21 CFR Part 11

Part 11 governs the use of electronic records and signatures to ensure they are as reliable as their paper counterparts. Its objectives include ensuring the authenticity, integrity, and traceability of electronic data.

Core requirements include:

• System Validation: Ensuring systems perform reliably and consistently.
• Audit Trails: Tracking all changes to records.
• Access Controls: Restricting data access to authorized personnel.
• Electronic Signatures: Linking signatures to their corresponding records.

Compliance vs. Compatibility

Using a Part 11-compatible system is a good starting point, but it’s not enough. Compatibility means the system has features that can support compliance, such as audit trails and user controls. Compliance, however, requires proper governance, processes, and training.

What to Do When Systems Are Not Compatible or Compliant

For startups using systems that fall short in compatibility or compliance, solutions exist. Addressing these issues proactively can save time and prevent costly setbacks:

1. Assess System Gaps: Conduct a gap analysis to identify missing features or functionalities in your systems. Engage with the vendor to understand the limitations and determine if upgrades or additional configurations are possible.
2. Implement Procedural Workarounds: If your system lacks certain compliance features, establish robust standard operating procedures (SOPs) to address these gaps. For instance, in one case, manual audit trail reviews became an interim solution while a company planned its long-term CSV strategy.
3. Leverage Third-Party Tools: Consider integrating third-party software to enhance existing system capabilities. Tools that provide audit trail management or validation support can bridge gaps while maintaining compliance.
4. Train Personnel Extensively: Equip your team with detailed training to handle non-compliant systems effectively. In one instance, an employee’s confusion about deleting results underscored the importance of well-defined SOPs and training.
5. Plan for Future Investments: While short-term fixes can address immediate needs, long-term planning should focus on transitioning to compliant systems. One client’s hybrid approach, combining electronic and paper records, mitigated risks while paving the way for system upgrades.

Lessons from the Field

Failures in CSV can create vulnerabilities. For example, an HPLC system permitted uncontrolled data generation through its operation panel, highlighting risks such as the absence of audit trails to monitor changes or the lack of access restrictions to prevent unauthorized modifications. These gaps emphasize the importance of addressing unvalidated systems to mitigate operational risks effectively. By physically disabling this feature, a company ensured stricter controls and mitigated risks. Such proactive measures demonstrate the importance of combining technological fixes with operational safeguards.

Why Compliance Matters

Non-compliance can lead to severe consequences, from rejected submissions to tarnished reputations. More importantly, it’s about safeguarding the integrity of the data that underpins every decision in pharmaceutical development.

Many startups seek regulatory consulting to help navigate these compliance challenges and align their operations with regulatory expectations. Another critical aspect is quality assurance in clinical trials, ensuring that all procedures and documentation adhere to the highest industry standards.

By bridging the gap between technology and governance, startups can achieve not just compliance but also operational excellence. Startups aiming to navigate the complexities of 21 CFR Part 11 can gain actionable insights here to align their operations with regulatory expectations.

You are invited to watch the next YouTube video for more information on the topic